Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reflects skepticism about the effect of free medications, with comments like 'adherence averaged just 41-55%' and 'less than half of post-MI patients took meds after a year,' emphasizing doubts about financial incentives alone driving behavioral change. Words like 'amaze' and 'obvious' show mixed feelings, capturing curiosity but also frustration regarding the complexity of medication adherence.
Most discussions highlight the limited effect of free medications on adherence, indicating mixed views on the effectiveness of reducing co-pays.
Posts show moderate interest, as many are curious about the findings but do not dive deeply into detailed implications.
Several users question or critique the results, reflecting some engagement but not extensive or detailed analysis.
The discussions suggest the findings have some significance in health policy debates but do not indicate a groundbreaking shift.
This paper will always amaze me Among patients who *had a heart attack* and *faced no cost sharing* adherence to key prescribed medications (ACE inhibitors/statins/beta-blockers) averaged just 41-55% https://t.co/vXbAZZ7IPm
@mikejohansenmd @leftbundle @drjohnm @Ed_Gerst @DrLindaDykes @pash22 @mancunianmedic @DrAoifeMolloy @MarshallProf @drtimwilson @AndrewFoy82 @AFPJournal Behavior change is very hard. Less than half of people who had an MI and got free meds were taking them after a year in MI-FREEE. Idea that more information will fix this problem that a ride in ambulance and trip to cath lab didn't seems unlikely to me. https://t.co/UxnZusdTNn
Good to study nudges, but our priors should be extremely pessimistic given that a) adherence is a mere surrogate and b) MI-FREE found that free meds made no difference in post MI outcomes. https://t.co/rsdxuMJh2m https://t.co/XJLx86DMes
薬を服用し続けるのは相当難しいんですね。例えば、心筋梗塞後の患者で、薬を無料で提供されても、スタチン服用を継続できるのは40%程度。Verve Therapeuticsはゲノム編集技術を用いてこの領域の課題を解決しようとしている。 https://t.co/fBupayDzdj
In an RCT of patients *discharged due to a heart attack* who faced *no cost for drugs*, adherence for critical meds (ACE/statins/B blockers) was at or below about 50%. I know I'm late to this study but man that is amazing. https://t.co/vXbAZZ7IPm
A #Pharmacoequity Throwback Thursday. Classic findings from The MI FREEE trial. “Enhanced prescription coverage improved medication adherence & rates of first major vascular events & decreased patient spending without increasing overall health costs.” https://t.co/l18qJthJFj https://t.co/AiGOfUOfMS
Providing full prescription coverage after a myocardial infarction increased medication adherence slightly and reduced major vascular events and revascularization rates without raising healthcare costs.
A bold trial in valvular heart disease and a cardiovascular prevention trial highlight the importance of humility in medical practice. Discussing new approaches to TAVI, CV risk management, and the impact of full…
A multicenter trial with 4146 patients found that adding coronary CT angiography to standard care reduced the 5-year risk of death from coronary heart disease or nonfatal myocardial infarction, improving patient…
RT @drjohnm: Good to study nudges, but our priors should be extremely pessimistic given that a) adherence is a mere surrogate and b) MI-FRE…
Good to study nudges, but our priors should be extremely pessimistic given that a) adherence is a mere surrogate and b) MI-FREE found that free meds made no difference in post MI outcomes. https://t.co/rsdxuMJh2m https://t.co/XJLx86DMes
RT @ben_ippolito: This paper will always amaze me Among patients who *had a heart attack* and *faced no cost sharing* adherence to key p…
RT @ben_ippolito: This paper will always amaze me Among patients who *had a heart attack* and *faced no cost sharing* adherence to key p…
RT @ben_ippolito: This paper will always amaze me Among patients who *had a heart attack* and *faced no cost sharing* adherence to key p…
RT @ben_ippolito: This paper will always amaze me Among patients who *had a heart attack* and *faced no cost sharing* adherence to key p…
RT @ben_ippolito: This paper will always amaze me Among patients who *had a heart attack* and *faced no cost sharing* adherence to key p…
This paper will always amaze me Among patients who *had a heart attack* and *faced no cost sharing* adherence to key prescribed medications (ACE inhibitors/statins/beta-blockers) averaged just 41-55% https://t.co/vXbAZZ7IPm
4/ So what does this mean? Isn’t it obvious that lower copays might lead to better adherence and safe & effective
Paper: https://t.co/uIwMyV6AW2
@djc795 @UREssien @DrMarthaGulati @JAHA_AHA @nyugsom_iehe @gcfmd @HeartDocSadiya @mvaduganathan But the effect size in this observational study seems much larger than in this RCT. Why? https://t.co/UxnZurWioN
RT @UREssien: A #Pharmacoequity Throwback Thursday. Classic findings from The MI FREEE trial. “Enhanced prescription coverage improved m…
RT @UREssien: A #Pharmacoequity Throwback Thursday. Classic findings from The MI FREEE trial. “Enhanced prescription coverage improved m…
RT @UREssien: A #Pharmacoequity Throwback Thursday. Classic findings from The MI FREEE trial. “Enhanced prescription coverage improved m…
A #Pharmacoequity Throwback Thursday. Classic findings from The MI FREEE trial. “Enhanced prescription coverage improved medication adherence & rates of first major vascular events & decreased patient spending without increasing overall health costs.” https://t.co/l18qJthJFj https://t.co/AiGOfUOfMS
RT @ErinGillespieMD: Today's @HarvardHBS class in #behavioraleconomics discussed @niteeshchoudhry's MI FREE RCT ⚖️ in @NEJM
Today's @HarvardHBS class in #behavioraleconomics discussed @niteeshchoudhry's MI FREE RCT ⚖️ in @NEJM
薬を服用し続けるのは相当難しいんですね。例えば、心筋梗塞後の患者で、薬を無料で提供されても、スタチン服用を継続できるのは40%程度。Verve Therapeuticsはゲノム編集技術を用いてこの領域の課題を解決しようとしている。 https://t.co/fBupayDzdj
RT @ben_ippolito: In an RCT of patients *discharged due to a heart attack* who faced *no cost for drugs*, adherence for critical meds (ACE/…
RT @ben_ippolito: In an RCT of patients *discharged due to a heart attack* who faced *no cost for drugs*, adherence for critical meds (ACE/…
In an RCT of patients *discharged due to a heart attack* who faced *no cost for drugs*, adherence for critical meds (ACE/statins/B blockers) was at or below about 50%. I know I'm late to this study but man that is amazing. https://t.co/vXbAZZ7IPm
#oldiebutgoodie from @niteeshchoudhry et al @NEJM 2011 on impact of removing co-pays for ❤️meds: https://t.co/wWskWZhazJ ➡️Cluster RCT didn't meet primary endpoint, but med adherence + total vasc events + stroke improved. #financialtoxicity @fumikochino @EmelineAvikiMD #impsci
@jelevenson @venkmurthy @JoshuaBeckmanMD https://t.co/4C55RaQ2QF
@Maratosflier @VPrasadMDMPH Same thing in cardiology. An MI wasn't enough to get most patients to take medications provided for *free*. Yet folks claim a CCTA or genetic scores will do the trick: https://t.co/UxnZusdTNn
RT @lisabari: @rcurtisspalding Removing copays on highly effective medication/services/procedures is the basis of “value-based insurance de…
@rcurtisspalding Removing copays on highly effective medication/services/procedures is the basis of “value-based insurance design.” There’s probably more recent evidence of improved outcomes, but here’s one study: https://t.co/NQ5Giw98v5
@DavidLBrownMD @JoaoLCavalcante @khurramn1 @onco_cardiology @AChoiHeart @DrRyanPDaly @lesleejshaw @BeanlandsRob @Heart_SCCT @prcardio @MyASNC Strange that a ride in an ambulance, a few days in the hospital and a stent didn't seem to get much med adherence in MI-FREEE (~40-50%). Presumably lifestyle is lower. https://t.co/UxnZurWioN
@HeartOTXHeartMD Not so sure about co-pays in typical post-MI drugs. MI-FREEE trial showed that effect of $0 co-pays was small. It's true for some but not most. https://t.co/UxnZusdTNn
Full Coverage for Preventive Medications after Myocardial Infarction | NEJM https://t.co/JyQwS56jvp
RT @venkmurthy: @mikejohansenmd @leftbundle @drjohnm @Ed_Gerst @DrLindaDykes @pash22 @mancunianmedic @DrAoifeMolloy @MarshallProf @drtimwil…
RT @venkmurthy: @mikejohansenmd @leftbundle @drjohnm @Ed_Gerst @DrLindaDykes @pash22 @mancunianmedic @DrAoifeMolloy @MarshallProf @drtimwil…
RT @venkmurthy: @mikejohansenmd @leftbundle @drjohnm @Ed_Gerst @DrLindaDykes @pash22 @mancunianmedic @DrAoifeMolloy @MarshallProf @drtimwil…
RT @venkmurthy: @mikejohansenmd @leftbundle @drjohnm @Ed_Gerst @DrLindaDykes @pash22 @mancunianmedic @DrAoifeMolloy @MarshallProf @drtimwil…
RT @venkmurthy: @mikejohansenmd @leftbundle @drjohnm @Ed_Gerst @DrLindaDykes @pash22 @mancunianmedic @DrAoifeMolloy @MarshallProf @drtimwil…
@mikejohansenmd @leftbundle @drjohnm @Ed_Gerst @DrLindaDykes @pash22 @mancunianmedic @DrAoifeMolloy @MarshallProf @drtimwilson @AndrewFoy82 @AFPJournal Behavior change is very hard. Less than half of people who had an MI and got free meds were taking them after a year in MI-FREEE. Idea that more information will fix this problem that a ride in ambulance and trip to cath lab didn't seems unlikely to me. https://t.co/UxnZusdTNn
@AugieLindmark @younes776 https://t.co/T0wFb7mZ9P Here is a good read by @niteeshchoudhry on co-pay and preventive med subsidies after MI.
@KagiyamaNobu 間違いないですね。 これはもうChoudhryらの我々の領域で知っておくべき有名な研究があります。 自己負担なくてもという面白いものです。 https://t.co/7A9aDzaKbi #CardioJapan
@serioustaurean @anupampom @Doc_Tiger @RogueRad @francisdeng @anish_koka This may not be so different in the US. Only about half of post-MI pts took secondary prevention meds, even when totally FREE. https://t.co/tMNeF9qFxg
@TuckerGoodrich @the_hough @kdinbburg @Ulf_Ekelund @mackinprof @B_Holmer @KevinH_PhD @FatEmperor @HermanPontzer @virtahealth https://t.co/YPr9NVCblx
Following a heart attack only half of patients take their prescribed meds! Even when the meds are free! http://www.nejm.org/doi/full/10.1056/NEJMsa1107913?query=featured_home